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ABSTRACT 
Objective: The aim of this study was to investigate current management of the anti-
coagulated trauma patient in the Emergency Departments in England and Wales.   
Methods: A survey exploring management strategies for anti-coagulated trauma 
patients presenting to the ED was developed with two patient scenarios concerning 
assessment of coagulation status, reversal of INR, management of hypotension and 
management strategies for each patient. Numerical data are presented as 
percentages of total respondents to that particular question.  
Results: A total of 106 respondents from 166 hospitals replied to the survey, with 
24% of respondents working in a major trauma unit with a specialist neurosurgical 
unit. Variation was reported in the assessment and management strategies of the 
elderly anti-coagulated polytrauma patient described in scenario one. Variation was 
also evident in the responses between the neurosurgical and non-neurosurgical units 
for the head-injured, anti-coagulated trauma patient in scenario two.    
Conclusions: The results of this study highlight the similarities and variation in the 
management strategies used in the Emergency Departments in England and Wales 
for the elderly, anti-coagulated trauma patient. The variations in practice reported 
may be due to the differences evident in the available guidelines for these patients. 
What this study adds. 
 
What is already known? 
There is conflicting evidence regarding the effect of pre-injury warfarin and as a 
result, no internationally accepted, validated guidelines exist for the management of 
this patient group. 
What this study adds. 
A case-based questionnaire of 64% of Trusts in England and Wales participating in 
the Trauma Audit and Research Network, found variation in management strategies 
particularly with regard to the elderly, anti-coagulated trauma patient. This study 
provides important evidence that fully validated guidelines are required, in order to 
ensure a high level of standardised care and optimal patient outcomes. 
INTRODUCTION 
Major trauma accounts for over five million deaths worldwide each year and this 
number is predicted to increase to over eight million by 2010.[1] In the UK alone, 
trauma accounts for approximately 16,000 deaths and costs the NHS between £0.3 
and £0.4 billion in immediate treatment.[2,3] It has been reported that approximately 
one third of bleeding trauma patients present with a coagulopathy.[1,4] Research 
has demonstrated that coagulation defects that occur in trauma patients are complex 
and these abnormalities are caused by a number of interrelated factors including; 
pre-existing conditions, pre-injury oral anti-coagulant use, dilution of haemostatic 
factors by fluid resuscitation or blood transfusion, severe hypothermia, hypoperfusion 
and acidosis due to tissue damage from trauma.[5-7] 
It is reported that approximately 1% of the UK population are currently using 
anticoagulant therapy and it is predicted that this figure will continue to rise as the 
size of the elderly population increases.[8] Controversy exists in trauma research 
regarding the impact of pre-injury anti-coagulant use on trauma patients. Pre-injury 
warfarin has been reported to be an independent predictor of mortality in trauma 
patients.[9,10]  
There is conflicting evidence regarding the effect of pre-injury warfarin and as a 
result, no internationally accepted, validated guidelines exist for the management of 
this group.[5,10-13] One of the key recommendations in the National Audit Office 
Report “Major Trauma Care in England” (2010) stated that there is a need for 
Strategic Health Authorities to develop protocols for the effective delivery of major 
trauma care against the standards set out in national clinical guidelines.[14] In the 
absence of such guidelines, there is a risk that patients receive a standard of care 
that is “less than good standard”, as previously reported in 60% of major trauma 
cases in England.[15] The aim of this study was to investigate variation in current 
management of the anti-coagulated trauma patient in the Emergency Departments in 
England and Wales, thus highlighting the need and providing evidence for inclusion 
of this complex subgroup of patients, in future national trauma guidelines.  
METHODS 
A survey exploring management strategies for anti-coagulated trauma patients 
presenting to the ED was developed. Two patient scenarios were presented, which 
included a combination of closed and open-ended questions, with space provided to 
offer comments as required. A number of questions were open-ended in order not to 
lead the respondent into providing specific responses and to reduce the risk of 
introducing response bias. The survey was pre-tested by a number of non-
participating clinicians in Morriston Hospital, Swansea and was subsequently revised 
based on feedback received.  
Using a purposive sample, the survey was administered using a web-based form to 
one of the trauma leads in each of the hospitals participating in the Trauma Audit 
and Research Network (TARN) in England and Wales. The respondents were 
therefore asked to discuss their own practice in the survey. To improve initial 
response rate, a follow-up round of surveys was sent to the trauma leads after three 
months via email and repeated after another eight weeks. TARN currently receives 
patient data from all trauma receiving hospitals in England and Wales. Ethical 
approval was not required as all responses were anonymous. 
Numerical data are presented as percentages of total respondents to that particular 
question. Results are reported comparing responses for the neurosurgical centres 
(major trauma units) with the non-neurosurgical centres (non-major trauma centres) 
for both scenarios.  
RESULTS 
Characteristics of respondents 
A total of 106 respondents from 166 hospitals replied to the survey. This was a 64% 
response rate from the hospitals participating in TARN. Of these hospitals, 25 out of 
the 27 neurosurgical centres in England and Wales responded, with the remainder 
being from non-neurosurgical centres. Six of the included questionnaires had not 
completed scenario two.    
Scenario One 
Scenario 1: A polytrauma patient has been admitted to your ED. The patient is 70 years old and 
known to use warfarin for atrial fibrillation. On initial examination, the patient appears to have a 
closed abdominal injury with signs of shock. The patient’s has a respiratory rate of 25, heart rate 
of 130, blood pressure of 90/70 and a normal GCS. INR is 2.8. The patient has received one litre of 
normal saline during pre-hospital care. Assuming the trauma team is giving Tranexamic Acid and 
initiating imaging requests: 
1) How would you assess this patient’s coagulation status?  
 
2) Would you reverse the patient’s INR?  YES / NO   (Please circle) 
Comments: 
 
3) If yes, how would you reverse the INR?   (Please circle all applicable)  
  a) Vitamin K 
  b) Fresh frozen plasma 
  c) Pro-thrombin complements 
Comments: 
 
4) What INR range are you aiming to achieve through reversal?  
 
5) Would you treat the patient’s hypotension?  YES / NO (Please circle)  
 
6a) If yes, what would be your initial treatment for the hypotension?  
 
Type of treatment:  Volume:  Rate of infusion:    
 
6b) What is your target BP?  
 
6c) If yes, what would be your on-going treatment for the hypotension? 
 
Type of treatment:   Volume:    
  
7) Would you treat the hypotension differently due to the pre-injury warfarin use (compared to a 
patient not using warfarin pre-injury?    YES / NO (Please circle) 
Comments: 
Table 1 outlines how the respondents would assess the patient’s coagulation status.  
Table 1: Methods used to assess patient’s coagulation status  
Method of assessment Number (%) 
n=102 
Neurosurgical 
unit number (%) 
n=25 
Non-neurosurgical 
unit number (%) 
n=77 
INR / near patient INR  67 (65.7%) 12 (48%) 55 (71%) 
Coagulation  / clotting screen  48 (47.1%) 9 (36%) 39 (51%) 
Liver function tests 3 (2.9%) 1 (4%) 2 (3%) 
Laboratory tests (not specified) 8 (7.8%) 2 (8%) 6 (8%) 
ROTEM or TEG 11 (10.8%) 7 (28%) 4 (5%) 
Full blood count 15 (14.7%) 3 (12%) 12 (16%) 
Clinical findings 8 (7.8%) 2 (8%) 6 (8%) 
Platelets 6 (5.9%) 2(8%) 4 (5%) 
Fibrinogen / FDP 16 (15.7%) 3(12%) 13 (17%) 
Activated partial thromboplastin time 16 (15.7%) 2 (8%) 14 (18%) 
Prothrombin Time 6 (5.9%) 2 (8%) 4 (5%) 
Other  6 (5.9%) 4 (16%) 2 (3%) 
Liaise with haematology 2 (2.0%) 0 (0%) 2 (3%) 
INR: International normalised ratio; TEG: Thromboelastography;  ROTEM: thromboelastometry 
Other: haemoglobin, thrombin time, intracellular calcium, arterial and venous blood gases, D Dimer 
and U&Es. 
Free text box used so any number of responses permitted. Total respondents=102 
A total of 105 (99%) respondents stated that they would reverse the patient’s INR, 
demonstrating a consensus in management between the respondents from both 
neurosurgical and non-neurosurgical centres. Figure 1 highlights the products used 
by the respondents to reverse the patient’s INR. Respondents may have used either 
one or any combination of the products.   
Figure 1: Products used to reverse the patient’s INR  
For the target INR range that respondents were aiming to achieve with their reversal 
strategies, a total of 21 different values / ranges of values were reported by the 
respondents, all ranging between the values of 1 and 2. The most commonly 
reported target INR (32%) in the neurosurgical centres was a ‘normal’ INR, 
compared to the non-neurosurgical units where the most commonly reported value 
(23%) was 1.5 or less.      
A total of 53% of respondents from the non-neurosurgical units stated they would 
treat the patient’s hypotension, compared with 80% of respondents from 
neurosurgical centres. The strategies used by the respondents for the on-going 
treatment of the patient’s hypotension have been grouped into “blood products” 
(including red cells, platelets, fresh frozen plasma and cryoprecipitate) or “fluids” 
(including crystalloids, normal saline, plasmalyte and hartmanns. Table 2 highlights 
the treatment strategy for on-going hypotension in the patient in Scenario 1.  
Table 2: Treatment strategies for on-going hypotension (if hypotension being 
treated) 
 Number (%) 
n=95 
Neurosurgical unit, 
number (%) n=18 
Non-neurosurgical 
unit, number (%) 
n=77 
Blood products 83 (87%) 14 (78%) 69 (90%) 
Fluids 23 (24%) 2 (11%) 21 (27%) 
Massive haemorrhage protocol 5 (5%) 2 (11%) 3 (4%) 
 
A total of 31% of respondents (from both neurosurgical and non-neurosurgical 
centres) stressed that the most important definitive treatment would be early CT 
imaging and surgery to identify and address the bleeding source. The volume and 
rate of each of the products that would be given by the respondents to treat the 
patient’s hypotension are described in Appendix A as a supplemental file.  
A total of 58% of respondents stated their target systolic blood pressure would be 
between 90 and 100, 32% stressed that they wouldn’t use blood pressure at all to 
assess the patient, and 7% stated that it would depend on whether the patient had a 
head injury or not. This was the general consensus from respondents in both 
neurosurgical and non-neurosurgical centres. 
A total of 32% of respondents from the non-neurosurgical centres stated that they 
would manage this trauma patient differently (compared to other trauma patients) as 
a result of their pre-injury anti-coagulant use. In the neurosurgical centres, a total of 
44% of respondents stated they would manage the patient differently. The main 
comments made by respondents from both neurosurgical and non-neurosurgical 
centres regarding the difference in management concerned the need for early 
reversal of the INR, the need for a higher threshold for suspicion of bleeding, in 
addition to greater aggressiveness in the correction of clotting abnormalities in the 
anti-coagulated trauma patient.    
Scenario 2 
Scenario 2: An elderly patient with an isolated head injury has been admitted to your ED. On 
examination, the patient is normotensive has no clinical signs of haemorrhage. The patient is 
known to use warfarin for AF and has an INR of 2.8. The patient has a GCS of 8. The patient has a 
small frontal contusion and a sub-dural haematoma on CT scan. Assuming the trauma team 
is considering CRASH 3: 
1) Is your ED in a hospital with a specialist neurosurgical unit?  YES / NO (please circle) 
   
2) What guidelines would you use to treat this patient?  
3) How would you assess this patient’s coagulation status? 
4) Would you reverse the patient’s INR?    YES / NO   (Please circle) 
Comments: 
5) If yes, how would you reverse the INR?   (Please circle all applicable)  
  a) Vitamin K 
  b) Fresh frozen plasma 
  c) Pro-thrombin complements 
Comments: 
6) What INR range are you aiming to achieve through reversal?  
A total of 100 responses (60% response rate) were received for the second scenario, 
with 25% of the respondents working in a specialist neurosurgical unit. Table 3 
highlights the guidelines that would be followed by respondents when managing the 
patient.  
Table 3: Guidelines used in the management of anti-coagulated trauma patient 
Guideline Number (%) 
n=94 
Neurosurgical unit 
number (%) n=24 
Non-neurosurgical 
unit number (%) n=70 
NICE Head Injury Guidelines  33 (35%) 8 (33%) 25 (36%) 
Local Trust Guidelines 30 (32%) 10 (42%) 20 (29%) 
Advanced Trauma Life Support 3 (3%) 0 (0%) 3 (4%) 
CRASH-3 on Tranexamic Acid 4 (4%) 0 (0%) 4 (6%) 
British Society of Haemotology 7 (7%) 2 (8%) 5 (7%) 
Regional Trauma or Neurosurgical 12 (13%) 2 (8%) 10 (14%) 
None needed 5 (5%) 0 (0%) 5 (7%) 
On-call neurologist 7 (7%) 1 (4%) 6 (9%) 
Other 5 (5%) 0 (0%) 5 (7%) 
CRASH-3: Clinical randomisation of Antifibrinolytic in significant head injury (Trial acronym) 
Free text box used so any number of responses permitted 
 
Table 4 highlights the methods the respondents would use to assess the patient’s 
coagulation status. There was a consensus between the two groups that a 
coagulation screen was the best method for assessing the patient’s coagulation 
status however, a greater number of respondents from the non-neurosurgical 
centres relied on INR. Fibrinogen was reported to be used in a higher percentage of 
respondents from the neurosurgical centres. 
Table 4: Methods used to assess patient’s coagulation status 
Method of assessment Number of 
responses (%) 
n=98 
Neurosurgical 
unit number (%) 
n=25 
Non-
neurosurgical unit 
number (%) n=73 
INR / near patient INR  57 (58%) 10 (40%) 47 (64%) 
Coagulation screen  46 (47%) 12 (48%) 34 (47%) 
Liver function tests 4 (4%) 2 (8%) 2 (3%) 
ROTEM or TEG 4 (4%) 2 (8%) 2 (3%) 
Full blood count 8 (8%) 2 (8%) 6 (8%) 
Clinical findings 2 (2%) 2 (8%) 0 (0%) 
Platelets 7 (7%) 1 (4%) 6 (8%) 
Fibrinogen / FDP 10 (10%) 7 (28%) 2 (3%) 
Activated partial thromboplastin time 11 (11%) 1 (4%) 10 (14%) 
Partial Prothrombin time 2 (2%) 0 (0%) 2 (3%) 
Prothrombin Time 6 (6%) 2 (8%) 4 (5%) 
Other 4 (4%) 1 (4%) 3 (4%)  
No further assessment required 8 (8%) 4 (16%) 4 (5%) 
INR: International normalised ratio; TEG: Thromboelastography;  ROTEM: thromboelastometry 
Other:  haemoglobin, liaise with the on-call haematologist, intracellular calcium and arterial / venous 
blood gases. 
Free text box used so any number of responses permitted. Total respondents=98 
A total of 97% of respondents stated that they would reverse the patient’s INR in this 
scenario, with the 3% who wouldn’t reverse it, working in a non-neurosurgical centre. 
Figure 2 highlights the products used by the respondents to reverse the patient’s 
INR.  
Figure 2: Products used to reverse the patient’s INR  
The INR value or range that respondents were aiming to achieve for the patient in 
scenario two with their reversal strategies ranged between 1 and 2, with a total of 19 
different responses given. The most commonly reported target INR value (33%) for 
the neurosurgical centres was an INR of 1, compared to the non-neurosurgical 
centres where the most commonly reported value (20%) was 1.5 or less.      
DISCUSSION 
This study has identified the similarities and differences in treatment strategies used 
in England and Wales, to manage the elderly, anti-coagulated trauma patient 
presenting to the ED. Hanley (2004) commented that pronounced differences exist in 
the recommendations within guidelines regarding management of an elderly anti-
coagulated trauma patient.[16] The results of this study have highlighted that a 
number of different guidelines are used by the respondents in current practice. 
Furthermore, a number of respondents who work at non-neurosurgical centres 
suggested that they did not use any guidelines to manage such patients.  
The most commonly used guideline (NICE Head Injury Guidelines) only discusses 
the use of CT scan in this specific patient group and contains no recommendation 
regarding reversal of anti-coagulant therapy.[17] The British Society of Haematology 
guidelines recommends the use of IV or oral Vitamin K in combination with PCC or 
FFP (if PCC not available) for the reversal of warfarin in the bleeding major trauma 
patient.[18] It is beyond the scope of this study to comment on similarities or 
variations in the content of each individual regional or local guidelines. It is evident 
however that there are no national guidelines that focus solely on the elderly, anti-
coagulated trauma patient, that consider all aspects of management.  
When considering both scenarios presented in the survey, there was an overall 
consensus that the patients’ INR should be reversed. The methods used to assess 
the patient’s coagulation status varied between the respondents. The most 
commonly used methods to assess coagulation status were INR and a clotting / 
coagulation screen, in both neurosurgical and non-neurosurgical centres.  Recent 
research has suggested however that these tests monitor only the initiation phase of 
blood coagulation therefore it is possible that the conventional coagulation screen 
appears normal, while the overall state of blood coagulation (clot stability, lysis or 
platelet function) is abnormal.[4,19] It is suggested that in addition to routine 
coagulation tests, viscoelastic methods also be performed to assist in characterising 
the coagulopathy and in guiding haemostatic therapy, however further research is 
needed.[4,19] A number of respondents commented that they would like to use such 
methods, but the equipment was not available at their ED. This lack of access to 
equipment invariably contributes to obvious differences in management of this 
patient group.     
The products used to reverse the patient’s INR varied between respondents. Current 
available guidelines recommend the use of PCC for the reversal of vitamin K- 
dependent oral anticoagulants in bleeding trauma patients and this was the most 
commonly reported product used by the respondents.[1,20,21]  It is evident that 
there is a lack of consensus in the guidelines regarding the use of other products for 
the reversal of INR in a bleeding trauma patient. 
Permissive hypotension for bleeding trauma patients is a relatively new concept in 
the management of bleeding and coagulopathy in major trauma patients. This 
approach avoids the adverse effects of early aggressive fluid resuscitation while 
maintaining an adequate level of tissue perfusion.[1,6,7] Current research 
recommends that good quality evidence underpinning permissive hypotension is 
limited and this may explain the fact that over half of the respondents would treat the 
hypotension of the patient in scenario one.  
There are a number of potential limitations in this study. One of the inherent 
problems with a survey study is achieving a sufficient response rate. In this study, 
65% of hospitals contacted to complete the survey were represented therefore non-
response bias may have occurred. Similarly, there was a number of missing data 
fields in the completed surveys which may have introduced an element of bias. 
Misinterpretation of questions within the survey should be considered, however the 
survey was piloted and subsequently adapted, which should have reduced this 
inaccuracy.    
CONCLUSIONS  
Despite the inherent potential biases in an investigation using a survey for data 
collection, the results of this study highlight the similarities and variation in the 
management strategies used in the Emergency Departments in England and Wales 
for the elderly, anti-coagulated trauma patient. The variations in practice reported 
may be due to the differences evident in the available guidelines for these patients. 
In the absence of fully validated, national clinical guidelines, there is a risk of sub-
optimal care and outcomes for the elderly, anti-coagulated major trauma patients. As 
a result of the variation in current practice reported in this study, the need for the 
specific inclusion of this complex, subgroup of major trauma patients, in future 
national guidelines has been highlighted.  
Acknowledgements: We would like to thank all the respondents who took time to 
complete the survey.  
Competing interests: None to declare 
Funding: None to declare 
REFERENCES 
1) Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy 
following major trauma: an updated European guideline. Crit Care 2013;17:R76. 
2) Davenport RA, Tai N, West A, et al. A major trauma centre is a specialty hospital 
not a hospital of specialties. Br J Surg 2011;97:109-117. 
3) National Audit Office. Major trauma care in England. 2010.                                 
http://www.nao.org.uk/wp-content/uploads/2010/02/0910213es.pdf   
4) Brohi K, Singh J, Heron M, et al. Acute traumatic coagulopathy. J Trauma 
2003;54:1127-1130. 
5) DeLoughery TG. Coagulation defects in trauma patients: aetiology, recognition 
and therapy. Crit Care Clin 2004;20:13-24. 
6) Santry HP, Alam HB. Fluid resuscitation: past, present and the future. Shock 
2010;33:229-241. 
7) Harris T, Thomas R, Brohi K. Early fluid resuscitation in severe trauma. BMJ 
2012;345:e5752.  
8) Leiblich A, Mason S. Emergence management of minor head injury in 
anticoagulated patients.  Emerg Med J 2011;28:115-118. 
9) Dossett LA, Riesel JN, Griffin MR, Cotton BA. Prevalence and implication of 
preinjury warfarin use. Arch Surg 2011;146:565-570. 
10) Lecky FE, Omar M, Bouamra O, et al. The effect of pre-injury warfarin use on 
mortality rates in trauma patients: a European multicentre study. Emerg Med J 
Published online first February 5th 2015. doi:10.1136/emermed-2014-203959.   
11) Hackam DG, Kopp A, Redelmeier DA. Prognostic implications of warfarin 
cessation after major trauma: a population based cohort analysis. Circulation 
2005;111:2250-2256. 
12) Malone DL, Dunne J, Tracy K, Putnam AT, Scalea TM, Napolitano LM. Blood 
transfusion, independent of shock severity, is associated with worse outcome in 
trauma. J Trauma 2003;54:898-907.  
13) Santry HP, Alam HB. Fluid resuscitation: past, present and the future. Shock 
2010;33:229-241. 
14) National Audit Office. Major Trauma Care in England. February 2010. 
http://www.nao.org.uk/wp-content/uploads/2010/02/0910213.pdf   
15) The National Confidential Enquiry into Patient Outcome and Death. Trauma: 
Who cares? 2007. http://www.ncepod.org.uk/2007t.htm    
16) Hanley J. Warfarin reversal. Clin Pathol 2004;57:1132-1139. 
17) National Institute for Health and Care Excellence. Head injury: triage, 
assessment, investigation and early management of head injury in children, young 
people and adults. CG176. January 2014. http://www.nice.org.uk/guidance/CG176   
18) Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin 
- fourth edition. Brit J Haematol 2011;154:311-324. 
19) Lier H, Krep H, Schöchl H. Coagulation management in the treatment of multiple 
trauma. Anaesthesist 2009;58:1010-1026.  
20) Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the Vitamin 
K Antagonists. American College of Chest Physicians: Evidence-Based Clinical 
Practice Guidelines (8th Edition). Chest 2008; 133:160S–198S.  
21) Baker RI, Coughlin PB, Gallus AS, et al; the Warfarin Reversal Consensus 
Group. Warfarin reversal: consensus guidelines, on behalf of the Australasian 
Society of Thrombosis and Haemostasis. Med J Australia 2004;181:492–497. 
Figure legends: 
Figure 1: Products used to reverse the patient’s INR  
Respondents asked to tick which of the three products listed they would use (more than one response 
therefore permitted) 
Figure 2: Products used to reverse the patient’s INR  
Respondents asked to tick which of the three products listed they would use (more than one response 
therefore permitted) 
 
 
 
 
 
